{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:51:55Z","timestamp":1791921115614,"version":"4.3.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jaad.2024.09.046","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T16:13:50Z","timestamp":1728490430000},"page":"242-251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12\u00a0years: 2-year results from PEDIatric STudy in Atopic Dermatitis"],"prefix":"10.1016","volume":"92","author":[{"given":"Amy S.","family":"Paller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"de Bruin-Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Marcoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eulalia","family":"Baselga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania","family":"Oliveira de Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ledit R.F.","family":"Ardusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne G.M.A.","family":"Pasmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirna","family":"Toledo-Bahena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel C.","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Wine Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Ardeleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2024.09.046_bib1","doi-asserted-by":"crossref","DOI":"10.4081\/dr.2012.e1","article-title":"Atopic dermatitis in adolescence","volume":"4","author":"Ricci","year":"2012","journal-title":"Dermatol Reports"},{"issue":"2","key":"10.1016\/j.jaad.2024.09.046_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.aller.2012.03.001","article-title":"The International Study of Asthma and Allergies in Childhood (ISAAC) phase three: a global synthesis","volume":"41","author":"Mallol","year":"2013","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"4","key":"10.1016\/j.jaad.2024.09.046_bib3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","article-title":"Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10086","key":"10.1016\/j.jaad.2024.09.046_bib6","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jaad.2024.09.046_bib7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"10356","key":"10.1016\/j.jaad.2024.09.046_bib8","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jaad.2024.09.046_bib9","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.09.046_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-033507","article-title":"Protocol for a prospective, observational, longitudinal study in paediatric patients with moderate-to-severe atopic dermatitis (PEDISTAD): study objectives, design and methodology","volume":"10","author":"Paller","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.jaad.2024.09.046_bib11","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.jaad.2022.01.018","article-title":"Disease characteristics, comorbidities, treatment patterns and quality of life impact in children <12 years old with atopic dermatitis: interim results from the PEDISTAD real-world registry","volume":"87","author":"Paller","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.09.046_bib12","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/bjd.13662","article-title":"What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study","volume":"172","author":"Leshem","year":"2015","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.09.046_bib13","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/bjd.12590","article-title":"Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods","volume":"169","author":"Charman","year":"2013","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.09.046_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/bjd.12232","article-title":"The Dermatitis Family Impact questionnaire: a review of its measurement properties and clinical application","volume":"169","author":"Dodington","year":"2013","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2024.09.046_bib15","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1111\/all.14324","article-title":"Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: results from the BioDay registry","volume":"75","author":"Spekhorst","year":"2020","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.jaad.2024.09.046_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13979","article-title":"Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients","volume":"33","author":"Dal Bello","year":"2020","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.jaad.2024.09.046_bib17","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1080\/09546634.2022.2067818","article-title":"Drug survival analysis of dupilumab and cyclosporin in patients with atopic dermatitis: a multicenter study","volume":"33","author":"Napolitano","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"10.1016\/j.jaad.2024.09.046_bib18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/pde.14909","article-title":"Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis\u2013a pooled analysis of trial data","volume":"39","author":"Paller","year":"2022","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.09.046_bib19","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-019-00445-7","article-title":"Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis","volume":"20","author":"Eichenfield","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.09.046_bib20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2017.09.052","article-title":"Risk of infection in patients with\u00a0atopic dermatitis treated with dupilumab: a meta-analysis of\u00a0randomized controlled trials","volume":"78","author":"Fleming","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.09.046_bib21","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jaip.2021.11.034","article-title":"Dupilumab treatment reduces hospitalizations in adults with moderate-to-severe atopic dermatitis","volume":"10","author":"Silverberg","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.jaad.2024.09.046_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2022.06.435","article-title":"Skin infections and antimicrobial use among patients with atopic dermatitis before and after initiating dupilumab treatment: a real-world study","volume":"87","author":"Ong","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2024.09.046_bib23","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jaad.2020.11.037","article-title":"Bidirectional association between atopic dermatitis, conjunctivitis, and other ocular surface diseases: a systematic review and meta-analysis","volume":"85","author":"Ravn","year":"2021","journal-title":"J Am Acad Dermatol"}],"updated-by":[{"DOI":"10.1016\/j.jaad.2026.06.106","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000}},{"DOI":"10.1016\/j.jaad.2026.06.106","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000}}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224029190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224029190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:35:03Z","timestamp":1791920103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962224029190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0190962224029190"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2024.09.046","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12\u00a0years: 2-year results from PEDIatric STudy in Atopic Dermatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2024.09.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}